安罗替尼治疗四肢韧带样纤维瘤有效性和安全性的回顾性研究

  目的  评估安罗替尼在四肢韧带样纤维瘤（desmoid-type fibromatosis，DF）患者治疗中的有效性和安全性。  方法  回顾性分析2019年1月至2020年4月于四川大学华西医院接受安罗替尼治疗的26例四肢DF患者的临床及随访资料。  结果  26例患者均定期随访，中位随访时间为14（11.75～16）个月。随访期间，无完全缓解（complete respons，CR）患者，10例（38.5%）部分缓解（partial response，PR)，12例（46.1%）疾病稳定（stable disease，SD），4例（15.4%）疾病进展（progressive disease，PD）。疾病控制率（disease control rate，DCR）为84.6%（22/26），客观缓解率（objective response rate，ORR）为38.5%（10/26）。6个月和12个月的无进展生存期（progression-free survival，PFS）分别为92.3%和84.6%。18例（69.2%）肿瘤体积缩小，22例（84.6%）肿瘤病灶核磁共振T2（magnetic resonance imaging T2，MRIT2）信号值降低，22例（84.6%）疼痛减轻，19例（73.1%）肿瘤邻近关节活动度改善。所有患者对安罗替尼不良反应均可耐受。  结论  安罗替尼对于四肢DF具有一定的疗效，可显著延缓疾病进展，提高患者生存质量，且患者对其不良反应可耐受。 

Efficacy and safety of anlotinib for patients with extremity desmoid-type fibromatosis:a retrospective study

  Objective  To evaluate the efficacy and safety of anlotinib in patients with extremity desmoid-type fibromatosis (DF).   Methods  Clinical and follow-up data of 26 patients with extremity DF who received anlotinib between January 2019 and April 2020 in West China Hospital were retrospectively analyzed .  Results  All the 32 patients were followed up regularly with a median follow-up of 14 (11.75-16) months. At last follow-up, none of the patients achieved a complete response (CR), but ten patients (38.5%) achieved a partial response (PR) and twelve patients (46.1%) achieved stable disease (SD), four patients (15.4%) developed progressive disease (PD) and the 6-, 12-month progression-free survival (PFS) rates were 92.3%, 84.6% respectively. The disease control rate (DCR) was 84.6% (22/26) and the objective response rate (ORR) was 38.5% (10/26). Meanwhile, a reduction in tumor size was achieved in eighteen patients (69.2%), a decrease in T2-weighted signal intensity on magnetic resonance imaging (MRIT2) was observed in 22 patients (84.6%), a subjective diminishment in local pain was described in 25 patients (96.2%), and an improvement in the range of motion of adjacent joints was examined in nineteen patients (73.1%) after anlotinib treatment. Additionally, anlotinib-induced toxicities were tolerated for all patients with extremity DF.  Conclusions  Anlotinib was effective against extremity DF and significantly slowed the disease progression to finally improve the quality of patients’ life with an acceptable drug-related toxicity.